Multicenter, prospective research on prevalence and fibrosis stage distribution in Japanese NAFLD patients using with ultrasound elastography [FibroScan] and Fib4 index

Not Applicable

Recruiting

• Conditions: onalcoholic fatty liver disease (NAFLD)

• Registration Number: JPRN-UMIN000035188
• Lead Sponsor: Yokohama City University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-12-09
• Study Completion: 2022-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 10000

Inclusion Criteria

Not provided

Exclusion Criteria

1. Alcohol consumption (ethanol equivalent volume), >=30 g/day for men, >=20 g/day for women, or >=210 g/day for men, >=140 g/day for women. 2. History of chronic hepatic disease (hemochromatosis, viral hepatic disease [hepatitis B or C], or autoimmune disease,[autoimmune hepatitis, primary biliary cholangitis]), thyroid disorder, lipoatrophy, parenteral nutrition, abetalipoproteinemia, alpha-1-antitrypsin deficiency, Wilson's disease, antiretroviral therapy, Reye's syndrome, HELLP syndrome, or inborn errors of metabolism (lecithin-cholesterol acyltransferase deficiency or lysosomal acid lipase deficiency) 3. Drug-induced liver disorder (amiodarone, methotrexate, tamoxifen, corticosteroids, valproic acid, and antiretroviral drugs)

Study & Design

• Study Type: Observational
• Study Design: Not specified